Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Aytu BioPharma, Inc. AYTU
$1.87
-$0.22 (-11.80%)
На 18:00, 12 мая 2023
+488.24%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
7859738.00000000
-
week52high
16.20
-
week52low
1.40
-
Revenue
96669000
-
P/E TTM
0
-
Beta
-0.40692000
-
EPS
-33.02000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 20:00
Описание компании
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 21 июл 2022 г. |
| Cantor Fitzgerald | Overweight | Overweight | 17 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 28 апр 2022 г. |
| Cantor Fitzgerald | Overweight | 30 мар 2021 г. | |
| Northland Securities | Outperform | 25 ноя 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Donofrio John Jr. | D | 15267 | 187804 | 21 дек 2022 г. |
| Cantrell Gary | D | 164089 | 40000 | 21 дек 2022 г. |
| DOCKERY CARL | D | 148805 | 40000 | 21 дек 2022 г. |
| Disbrow Joshua R. | D | 1151877 | 80000 | 20 дек 2022 г. |
| Disbrow Joshua R. | A | 1231877 | 112371 | 19 дек 2022 г. |
| PYSZCZYMUKA GREG | A | 182056 | 100000 | 19 дек 2022 г. |
| Oki Mark K | A | 190000 | 90000 | 18 ноя 2022 г. |
| Disbrow Joshua R. | A | 1119506 | 222000 | 18 ноя 2022 г. |
| Oki Mark K | A | 190000 | 90000 | 18 ноя 2022 г. |
| Disbrow Joshua R. | A | 1119506 | 222000 | 18 ноя 2022 г. |
Новостная лента
Aytu BioPharma, Inc. (AYTU) Q3 2023 Earnings Call Transcript
Seeking Alpha
11 мая 2023 г. в 21:57
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q3 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Roger Weiss - Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Naz Rahman - Maxim Group, LLC Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q3 Results Conference Call.
Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023
Accesswire
04 мая 2023 г. в 16:30
ENGLEWOOD, CO / ACCESSWIRE / May 4, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for its third quarter fiscal year 2023, ended March 31, 2023, after the market close on Thursday, May 11, 2023. The Company has scheduled a conference call that same day, Thursday, May 11, 2023, at 4:30 pm ET, to review the results.
Aytu BioPharma, Inc. (AYTU) Q2 2023 Earnings Call Transcript
Seeking Alpha
21 февр 2023 г. в 21:35
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q2 2023 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Roger Weiss - Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Vernon Bernardino - H.C. Wainwright Operator Greetings.
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023
Accesswire
21 февр 2023 г. в 15:00
ENGLEWOOD, CO / ACCESSWIRE / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for the quarter ended December 31, 2022, after the market close today, Tuesday, February 21, 2023. The Company has also scheduled a conference call for today, Tuesday, February 21, 2023, at 5:00 pm ET, to review the results.
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31
Accesswire
24 янв 2023 г. в 08:00
ENGLEWOOD, CO / ACCESSWIRE / January 24, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023. Company Webcast The Company's webcast presentation will be available for viewing at 9:00 am ET on Tuesday, January 31, 2023, on the Company's website at https://irdirect.net/AYTU or at https://wsw.com/webcast/lytham7/aytu/2069810.